Resources Antibody Industry Trends Antibody Therapeutics Against Cancer

Antibody Therapeutics Against Cancer

Biointron 2023-10-25 Read time: 4 mins
Antibody Therapeutics Against Cancer
Source: Getty Images

The last few decades have witnessed an acceleration in the discovery and development of therapeutic antibodies. They have revolutionized modern medicine, offering targeted therapies with high specificity and fewer side effects.

From monospecific human antibodies like erenumab for migraines, to bispecific murine antibodies like blinatumomab for cancer, therapeutic antibodies are highly valuable in treating various therapeutic areas, especially cancer. The number of FDA approvals for antibody drugs are quickly growing year by year.

Antibody Therapeutics Against Cancer

The steady increase in the number of FDA-approved therapeutic antibodies, especially for cancer, reflects the incredible advancements in antibody research and clinical trials. Antibodies are now highly diverse, with different formats such as VHH, scFv, and Fab antibodies, as well as different expression systems such as CHO cells, murine cells, and E. coli.

Cancer in particular is dominating the antibody therapeutics space, since monoclonal antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses.

Antibody Therapeutics Against Cancer

In the past year alone, five therapeutic antibodies for cancer have been approved.

  • Retifanlimab: Approved in March, this monospecific antibody targets PD-1 and is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma.

  • Epcoritamab: On May 19, this bispecific antibody was approved to treat relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

  • Glofitamab: Approved in June, this bispecific is also used to treat selected relapsed or refractory large B-cell lymphomas, but has a Fab-Fc x Fab-Fab-Fc format rather than a full-length format.

  • Talquetamab: On Aug 9, the FDA granted accelerated approval for relapsed or refractory multiple myeloma.

  • Elranatamab: The latest antibody cancer drug to be approved, this bispecific antibody also treats multiple myeloma by targeting the CD3 T-cell engager.

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.